Disease · EFO_0003907

deep vein thrombosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. deep vein thrombosis. Diseases, record EFO_0003907. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0003907

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: deep vein thrombosis; Open Targets
Open Targets ID: EFO_0003907; Open Targets
Other names: DVT, Deep Vein Thromboses, Deep Venous Thromboses, Deep Venous Thrombosis, Thromboses, Deep Vein, Thromboses, Deep Venous, Thrombosis, Deep Vein, Thrombosis, Deep Venous, Vein Thromboses, Deep, Vein Thrombosis, Deep, Venous Thromboses, Deep, Venous Thrombosis, Deep; Open Targets
NCI Thesaurus: C49343; NCI Thesaurus
Highest stage of its drugs: Approval, for 14 of its 48 drugs, from DailyMed, FDA, PMDA and TTD; Open Targets

Drugs48

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RIVAROXABAN	CHEMBL198362	Small molecule	Approval	DailyMed and TTD	33	30	29	Drugs and targets
APIXABAN	CHEMBL231779	Small molecule	Approval	DailyMed	18	15	14	Drugs and targets
DALTEPARIN SODIUM	CHEMBL1201460	Oligosaccharide	Approval	DailyMed	10	8	6	Drugs and targets
ENOXAPARIN SODIUM	CHEMBL1201476	Oligosaccharide	Approval	DailyMed	20	4	1	Drugs and targets
EDOXABAN	CHEMBL1269025	Small molecule	Approval	PMDA	5	4	4	Drugs and targets
TINZAPARIN SODIUM	CHEMBL1201414	Oligosaccharide	Approval	DailyMed	5	3	1	Drugs and targets
HEPARIN SODIUM	CHEMBL1201657	Oligosaccharide	Approval	DailyMed and TTD	32	2	1	Drugs and targets
FONDAPARINUX SODIUM	CHEMBL1200644	Oligosaccharide	Approval	DailyMed and PMDA	3	1	1	Drugs and targets
DESIRUDIN	CHEMBL1201662	Protein	Approval	FDA and TTD	2	0	0	Drugs and targets
CERTOPARIN SODIUM	CHEMBL2109012	Oligosaccharide	Approval	TTD	1	0	0	Drugs and targets

1 to 10 of 48

See all 48 drugs

Targets67

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SERPINC1	Antithrombin-III	10	Antithrombin-III activator	Approval	https://conductscience.org/library/genes/462	Drugs and targets
NR3C1	Glucocorticoid receptor	9	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
F10	Coagulation factor X	8	Coagulation factor X inhibitor	Approval	https://conductscience.org/library/genes/2159	Drugs and targets
F2	Prothrombin	4	Thrombin inhibitor	Approval	https://conductscience.org/library/genes/2147	Drugs and targets
VKORC1	Vitamin K epoxide reductase complex subunit 1	2	Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor	Phase 3	https://conductscience.org/library/genes/79001	Drugs and targets
COL11A1	Collagen	1	Collagen hydrolytic enzyme	Phase 2	https://conductscience.org/library/genes/1301	Drugs and targets
COL11A2	Collagen	1	Collagen hydrolytic enzyme	Phase 2	https://conductscience.org/library/genes/1302	Drugs and targets
COL15A1	Collagen	1	Collagen hydrolytic enzyme	Phase 2	https://conductscience.org/library/genes/1306	Drugs and targets
COL18A1	Collagen	1	Collagen hydrolytic enzyme	Phase 2	https://conductscience.org/library/genes/80781	Drugs and targets
COL1A1	Collagen	1	Collagen hydrolytic enzyme	Phase 2	https://conductscience.org/library/genes/1277	Drugs and targets

1 to 10 of 67

See all 67 targets

Trials80

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00643201	Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism	Phase 3	5,614	2014-04-10	Venous Thrombosis	APIXABAN, ENOXAPARIN, WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT00439777	Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study	Phase 3	4,833	2013-01-24	Pulmonary Embolism	RIVAROXABAN	Its record names the disease	ClinicalTrials.gov
NCT00440193	Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study	Phase 3	3,449	2013-01-24	Venous Thrombosis	RIVAROXABAN	Its record names the disease	ClinicalTrials.gov
NCT03045406	Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer	Phase 3	1,170	2025-06-18	Venous Thromboembolism	APIXABAN	Its record names the disease	ClinicalTrials.gov
NCT04504032	A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)	Phase 2	497	2021-10-22	COVID-19	RIVAROXABAN	Its record names the disease	ClinicalTrials.gov
NCT02585713	Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism	Phase 3	300	2019-12-24	Cerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis, Hepatic Thrombosis, Malignant Neoplasm, Mesenteric Thrombosis, Metastatic Malignant Neoplasm, Portal Vein Thrombosis, Pulmonary Embolism, Renal Vein Thrombosis, Splenic Thrombosis, Venous Thromboembolism	APIXABAN, DALTEPARIN SODIUM	Its record names the disease	ClinicalTrials.gov
NCT00633061	Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer	Phase 2	136	2019-03-08	Childhood Cancer, Central Venous Catheters, Deep Vein Thrombosis, Catheter-related Infection, Catheter-related Occlusion	ENOXAPARIN	Its record names the disease	ClinicalTrials.gov
NCT00480636	Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients		102	2010-08-10	Acute Deep Vein Thrombosis	DALTEPARIN SODIUM	Its record names the disease	ClinicalTrials.gov
NCT01662908	A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis	Phase 2	85	2017-05-12	Deep Vein Thrombosis, Venous Thrombosis	EDOXABAN, HEPARIN	Its record names the disease	ClinicalTrials.gov
NCT01780987	AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients	Phase 3	80	2016-06-23	Deep Vein Thrombosis, Pulmonary Embolism	APIXABAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 80

See all 80 trials

Comparisons in its trials32

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Apixaban vs Enoxaparin/Warfarin: serious adverse events	417 of 2,676	410 of 2,689	5,365	NCT00643201	Trial comparisons
Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin/VKA: serious adverse events	504 of 2,412	495 of 2,405	4,817	NCT00439777	Trial comparisons
Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin/VKA: serious adverse events	222 of 1,718	252 of 1,711	3,429	NCT00440193	Trial comparisons
Apixaban vs Dalteparin: Recurrent Venous Thromboembolism	32 of 576	46 of 579	1,155	NCT03045406	Trial comparisons
Apixaban vs Dalteparin: deaths from any cause	135 of 576	153 of 579	1,155	NCT03045406	Trial comparisons
Apixaban vs Dalteparin: serious adverse events	255 of 576	276 of 579	1,155	NCT03045406	Trial comparisons
Rivaroxaban vs Placebo: Number of Participants With AEs Resulting in Study Intervention Discontinuation Through Day 35	4 of 219	5 of 230	449	NCT04504032	Trial comparisons
Rivaroxaban vs Placebo: Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) Through Day 35	6 of 219	13 of 230	449	NCT04504032	Trial comparisons
Rivaroxaban vs Placebo: Number of Participants With Serious Adverse Events Through Day 35	2 of 219	7 of 230	449	NCT04504032	Trial comparisons
Rivaroxaban vs Placebo: deaths from any cause	0 of 219	0 of 230	449	NCT04504032	Trial comparisons

1 to 10 of 32

See all 32 comparisons in its trials

Papers from its trials95

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39491572	RESULT	1	PubMed
35041203	RESULT	1	PubMed
35027972	RESULT	1	PubMed
33363402	RESULT	1	PubMed
32082717	RESULT	1	PubMed
31706868	RESULT	1	PubMed
31630479	RESULT	2	PubMed
31596449	RESULT	1	PubMed
31504429	RESULT	1	PubMed
30918939	RESULT	1	PubMed

1 to 10 of 95

See all 95 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0003907

GET https://conductscience.org/api/diseases/v1/EFO_0003907/drugs?page=2

API reference For AI assistants